Cui Ping Gu

Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China.

NuProbe USA, Inc. engages in the development of ultra-sensitive and multiplexed platform with reagents for non-invasive nucleic acid profiling and diagnostics. The firm offers VarTrace EGFR Assay, VarTrace BFAR Assay, and VarTrace AML multi-gene panel. The company was founded by Peng Yin, David Yu Zhang, and Victor Chenyang Shi in 2016 and is headquartered in Cambridge, MA.

Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China.

Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China.

Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China.

NuProbe USA, Inc. engages in the development of ultra-sensitive and multiplexed platform with reagents for non-invasive nucleic acid profiling and diagnostics. The firm offers VarTrace EGFR Assay, VarTrace BFAR Assay, and VarTrace AML multi-gene panel. The company was founded by Peng Yin, David Yu Zhang, and Victor Chenyang Shi in 2016 and is headquartered in Cambridge, MA.

Silicon Therapeutics LLC operates as an integrated computational drug discovery company that focuses on developing novel medicines for diseases. Its INSITE platform closely represents the dynamical nature of targets using all-atom simulations. The firm has offices in Boston and Shanghai. The company was founded by Lijun Sun, Peiqi Sun, Elliot L. Chaikof, and Finith Jernigan, III in 2016 and is headquartered in Boston, MA.

Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA.

Silicon Therapeutics LLC operates as an integrated computational drug discovery company that focuses on developing novel medicines for diseases. Its INSITE platform closely represents the dynamical nature of targets using all-atom simulations. The firm has offices in Boston and Shanghai. The company was founded by Lijun Sun, Peiqi Sun, Elliot L. Chaikof, and Finith Jernigan, III in 2016 and is headquartered in Boston, MA.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China.

Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA.

NuProbe USA, Inc. engages in the development of ultra-sensitive and multiplexed platform with reagents for non-invasive nucleic acid profiling and diagnostics. The firm offers VarTrace EGFR Assay, VarTrace BFAR Assay, and VarTrace AML multi-gene panel. The company was founded by Peng Yin, David Yu Zhang, and Victor Chenyang Shi in 2016 and is headquartered in Cambridge, MA.

Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

NuProbe USA, Inc. engages in the development of ultra-sensitive and multiplexed platform with reagents for non-invasive nucleic acid profiling and diagnostics. The firm offers VarTrace EGFR Assay, VarTrace BFAR Assay, and VarTrace AML multi-gene panel. The company was founded by Peng Yin, David Yu Zhang, and Victor Chenyang Shi in 2016 and is headquartered in Cambridge, MA.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China.

Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin.

Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

NuProbe USA, Inc. engages in the development of ultra-sensitive and multiplexed platform with reagents for non-invasive nucleic acid profiling and diagnostics. The firm offers VarTrace EGFR Assay, VarTrace BFAR Assay, and VarTrace AML multi-gene panel. The company was founded by Peng Yin, David Yu Zhang, and Victor Chenyang Shi in 2016 and is headquartered in Cambridge, MA.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin.

Shenzhen Jingtai Technology Co., Ltd. is a company that researches and develops biotechnology products. The company is based in Shenzhen, China. The Chinese company was founded in 2015 by Shu Hao Wen, Jian Ma, Li Peng Lai. Jian Ma has been the CEO since 2015.

Shenzhen Jingtai Technology Co., Ltd. is a company that researches and develops biotechnology products. The company is based in Shenzhen, China. The Chinese company was founded in 2015 by Shu Hao Wen, Jian Ma, Li Peng Lai. Jian Ma has been the CEO since 2015.

Shenzhen Jingtai Technology Co., Ltd. is a company that researches and develops biotechnology products. The company is based in Shenzhen, China. The Chinese company was founded in 2015 by Shu Hao Wen, Jian Ma, Li Peng Lai. Jian Ma has been the CEO since 2015.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Shenzhen Jingtai Technology Co., Ltd. is a company that researches and develops biotechnology products. The company is based in Shenzhen, China. The Chinese company was founded in 2015 by Shu Hao Wen, Jian Ma, Li Peng Lai. Jian Ma has been the CEO since 2015.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin.

Shenzhen Jingtai Technology Co., Ltd. is a company that researches and develops biotechnology products. The company is based in Shenzhen, China. The Chinese company was founded in 2015 by Shu Hao Wen, Jian Ma, Li Peng Lai. Jian Ma has been the CEO since 2015.

Silicon Therapeutics LLC operates as an integrated computational drug discovery company that focuses on developing novel medicines for diseases. Its INSITE platform closely represents the dynamical nature of targets using all-atom simulations. The firm has offices in Boston and Shanghai. The company was founded by Lijun Sun, Peiqi Sun, Elliot L. Chaikof, and Finith Jernigan, III in 2016 and is headquartered in Boston, MA.

Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Shenzhen Jingtai Technology Co., Ltd. is a company that researches and develops biotechnology products. The company is based in Shenzhen, China. The Chinese company was founded in 2015 by Shu Hao Wen, Jian Ma, Li Peng Lai. Jian Ma has been the CEO since 2015.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong.

NuProbe USA, Inc. engages in the development of ultra-sensitive and multiplexed platform with reagents for non-invasive nucleic acid profiling and diagnostics. The firm offers VarTrace EGFR Assay, VarTrace BFAR Assay, and VarTrace AML multi-gene panel. The company was founded by Peng Yin, David Yu Zhang, and Victor Chenyang Shi in 2016 and is headquartered in Cambridge, MA.